Abiopharma

News list

📋 Readnour Robin Shane (Director) plans to sell 1.0M shares of AN2 Therapeutics, Inc. (at $6.01 each, total $6.1M) Filed: Aug 17, 2026 | ID: 000263

Full text

News bot Aug. 17, 2026, 8:25 p.m.
📋 Form 144 Filing: Readnour Robin Shane

Company: AN2 Therapeutics, Inc.

Filing Date: 2026-08-17

Relationship: Director
Planned Sale Details:
- Security: Common Stock
- Shares to be Sold: 1,012,000
- Price per Share: $6.01
- Total Value: $6,080,268.00
- Planned Sale Date: 2026-08-17
- Broker: Stifel Nicolaus & Company Inc
- Exchange: Nasdaq
Additional Information:
- SEC File Number: 001-41331
- Issuer Contact Phone: (650) 331-9090
- Issuer Address: 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Broker Address: 501 N Broadway, St. Louis, MO, 63102
- Shares Outstanding: 37736237.0
- Number of Securities to be Sold: 4
- Remarks: Shares sold under MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP pursuant to their respective 10b5-1 plan
- Signature: /s/ Azad Daswani, as a duly authorized representative of STIFEL, as attorney-in-fact for Robin Readnor